News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
713,191 Results
Type
Article (42256)
Company Profile (436)
Press Release (670499)
Multimedia
Podcasts (76)
Webinars (13)
Section
Business (208711)
Career Advice (2021)
Deals (36003)
Drug Delivery (104)
Drug Development (83566)
Employer Resources (173)
FDA (16421)
Job Trends (15091)
News (352742)
Policy (33070)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (5)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2642)
Accelerated approval (6)
Adcomms (24)
Allergies (84)
Alliances (50930)
ALS (92)
Alzheimer's disease (1420)
Antibody-drug conjugate (ADC) (127)
Approvals (16409)
Artificial intelligence (257)
Autoimmune disease (24)
Automation (15)
Bankruptcy (372)
Best Places to Work (11841)
BIOSECURE Act (18)
Biosimilars (105)
Biotechnology (330)
Bladder cancer (65)
Brain cancer (26)
Breast cancer (270)
Cancer (2143)
Cardiovascular disease (179)
Career advice (1687)
Career pathing (29)
CAR-T (150)
Cell therapy (426)
Cervical cancer (19)
Clinical research (67634)
Collaboration (838)
Compensation (516)
Complete response letters (24)
COVID-19 (2642)
CRISPR (42)
C-suite (235)
Cystic fibrosis (105)
Data (2083)
Decentralized trials (2)
Denatured (27)
Depression (47)
Diabetes (261)
Diagnostics (6408)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (105)
Drug shortages (26)
Duchenne muscular dystrophy (98)
Earnings (87578)
Editorial (39)
Employer branding (21)
Employer resources (147)
Events (115448)
Executive appointments (712)
FDA (17626)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (754)
Gene editing (109)
Generative AI (20)
Gene therapy (312)
GLP-1 (737)
Government (4493)
Grass and pollen (4)
Guidances (51)
Healthcare (19143)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (123)
Indications (27)
Infectious disease (2785)
Inflammatory bowel disease (140)
Inflation Reduction Act (11)
Influenza (51)
Intellectual property (92)
Interviews (311)
IPO (16776)
IRA (43)
Job creations (3699)
Job search strategy (1434)
Kidney cancer (9)
Labor market (36)
Layoffs (489)
Leadership (17)
Legal (7982)
Liver cancer (73)
Lung cancer (309)
Lymphoma (141)
Machine learning (5)
Management (58)
Manufacturing (291)
MASH (65)
Medical device (13495)
Medtech (13500)
Mergers & acquisitions (19738)
Metabolic disorders (691)
Multiple sclerosis (77)
NASH (19)
Neurodegenerative disease (97)
Neuropsychiatric disorders (30)
Neuroscience (1964)
NextGen: Class of 2025 (6755)
Non-profit (4546)
Northern California (2565)
Now hiring (38)
Obesity (376)
Opinion (222)
Ovarian cancer (75)
Pain (84)
Pancreatic cancer (81)
Parkinson's disease (153)
Partnered (21)
Patents (225)
Patient recruitment (100)
Peanut (47)
People (58594)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21249)
Phase II (29842)
Phase III (22072)
Pipeline (1140)
Policy (138)
Postmarket research (2601)
Preclinical (9069)
Press Release (67)
Prostate cancer (101)
Psychedelics (37)
Radiopharmaceuticals (261)
Rare diseases (396)
Real estate (6014)
Recruiting (66)
Regulatory (22668)
Reports (46)
Research institute (2415)
Resumes & cover letters (351)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (73)
Series A (134)
Series B (87)
Service/supplier (11)
Sickle cell disease (57)
Southern California (2220)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (29)
Startups (3758)
State (2)
Stomach cancer (14)
Supply chain (66)
Tariffs (24)
The Weekly (47)
United States (22596)
Vaccines (688)
Venture capitalists (40)
Weight loss (250)
Women's health (36)
Worklife (16)
Date
Today (35)
Last 7 days (496)
Last 30 days (2425)
Last 365 days (33910)
2025 (9471)
2024 (36303)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27993)
Location
Africa (736)
Alabama (57)
Alaska (7)
Arizona (237)
Arkansas (14)
Asia (39170)
Australia (6524)
California (5914)
Canada (1952)
China (500)
Colorado (260)
Connecticut (275)
Delaware (137)
Europe (85582)
Florida (864)
Georgia (203)
Idaho (57)
Illinois (531)
India (25)
Indiana (304)
Iowa (10)
Japan (151)
Kansas (105)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (877)
Massachusetts (4514)
Michigan (217)
Minnesota (384)
Mississippi (2)
Missouri (79)
Montana (29)
Nebraska (25)
Nevada (60)
New Hampshire (66)
New Jersey (1693)
New Mexico (30)
New York (1673)
North Carolina (1003)
North Dakota (7)
Northern California (2565)
Ohio (197)
Oklahoma (14)
Oregon (37)
Pennsylvania (1320)
Puerto Rico (11)
Rhode Island (31)
South America (1110)
South Carolina (20)
South Dakota (1)
Southern California (2220)
Tennessee (99)
Texas (880)
Utah (174)
Virginia (140)
Washington D.C. (61)
Washington State (552)
West Virginia (3)
Wisconsin (52)
713,191 Results for "vtv therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
March 18, 2025
·
5 min read
Press Releases
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
March 20, 2025
·
11 min read
Press Releases
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference
December 3, 2024
·
2 min read
Bio NC
vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes
vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the first patient has been screened in the Company’s CATT1 pivotal trial evaluating cadisegliatin as an adjunct treatment of type 1 diabetes (T1D).
June 24, 2024
·
5 min read
Business
vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes (“T1D”), today reported financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate developments.
May 9, 2024
·
8 min read
Press Releases
vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update
November 12, 2024
·
7 min read
Drug Development
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
vTv Therapeutics Inc. today announced the submission of the study protocol to the FDA for the Company’s first Phase 3 trial evaluating the safety and efficacy of its lead candidate, cadisegliatin , in adults diagnosed with T1D.
March 4, 2024
·
4 min read
Bio NC
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes (“T1D”), today announced that Company management will be presenting at the TD Cowen 44th Annual Healthcare Conference, being held March 4-6, 2024, in Boston, MA.
March 1, 2024
·
3 min read
Business
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided an update on recent corporate developments.
March 13, 2024
·
10 min read
Bio NC
vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million
vTv Therapeutics Inc. announced that it has entered into a common stock repurchase agreement with Reneo Pharmaceuticals, Inc. through which Reneo has purchased all of its common stock that was granted to vTv under the Reneo License Agreement for total proceeds to vTv of approximately $4.4 million.
November 1, 2023
·
4 min read
1 of 71,320
Next
